Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 2, 2001, Pages 338-344

  Gulwadi, Amit G ^a   Korpinen, Carolyn D ^a   Mailman, Richard B ^b   Nichols, David E ^c   Sit, Sing Yuen ^a   Taber, Matthew T ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DINAPSOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; QUINPIROLE; RACLOPRIDE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; NAPHTHOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERANCE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICAL SYMPATHECTOMY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; NEOSTRIATUM; ROTATION; SPRAGUE DAWLEY RAT; STEREOTYPY;

ANIMALS; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HYDROXYDOPAMINES; ISOQUINOLINES; MALE; NAPHTHOLS; NEOSTRIATUM; PARKINSON DISEASE; QUINPIROLE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; ROTATION; STEREOTYPED BEHAVIOR; SYMPATHECTOMY, CHEMICAL;

EID: 0034746512     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 1 receptor stimulation on rotation and c-fos expression
2. 2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
3. Effects of full dopamine D1 receptor agonist Dihydrexidine in Parkinson's disease
4. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease
5. 1 full agonist
6. 2 agonist, as sole dopaminergic therapy in Parkinson's disease
7. Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval
8. 2 dopamine agonists in MPTP monkeys
9. Dose- and duration-dependent tolerance to rotational effects of apomorphine in a rat model of Parkinsonism
10. Time course of tolerance to apomorphine in Parkinsonism
11. 1 agonist containing a rigid β-phenyldopamine pharmacophore
12. Time interval between repeated injection conditions, the duration of motor improvement to apomorphine in Parkinson's disease
13. Biochemical models of Parkinson's disease
14. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
15. A clinicopathologic study of 100 cases of Parkinson's disease
16. 1 receptor agonist with antiparkinsonian activity in marmosets
17. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals
18. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
19. 1A dopamine receptor: Efficacy in causing desensitization dissociates from both receptor occupancy and functional potency
20. 1 receptor agonist
21. Functional effects of novel dopamine ligands: Dihydrexidine and Parkinson's disease as a first step
22. Parkinson's disease
23. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
24. 1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset
25. Does tolerance develop to levodopa? Comparison of 2 and 21 hour levodopa infusions
26. Use of apomorphine in Parkinson's disease
27. 1 receptor agonist prodrug, has efficacy in Parkinson's Disease
28. Behavioral sensitization: Characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats
29. Suppression of dyskinesia in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesia but not for relief of parkinsonism in patients with advanced Parkinson's disease
30. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: Analysis of functional deficits, recovery and treatments
31. 1 receptor agonist: In vitro characterization and effects in animal models of Parkinson's disease
32. 1 agonist, reduces MPTP-induced parkinsonism in monkeys
33. 1 dopamine receptor partial agonist CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmosets
34. 1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease
35. 6-Hydroxydopamine induced degeneration of the central monoamine neurons
36. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system in the rat brain
37. 1 dopamine receptors in primates and rodents: Comparison of full (dihydrexidine) and partial (SKF 38393) efficacy dopamine agonists
38. Reversal of supersensitive apomorphine-induced rotational behavior in mice by continuous exposure to apomorphine